Response to antiepileptic drug therapy: winners and losers.
Recent evidence suggests that the vast majority of people with epilepsy will respond to their first or second treatment regimen or will be refractory de novo. Two patients with symptomatic epilepsy secondary to underlying cortical dysplasias are presented to illustrate these different scenarios. Clinical observations can provide insights to the processes underlying pharmacoresistance.
Brodie
Martin J
MJ
Epilepsy Unit, Division of Cardiovascular and Medical Sciences, Western Infirmary, Glasgow, Scotland, U.K. Martin.J.Brodie@clinmed.gla.ac.uk
D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002220:Carbamazepine / Q000627:therapeutic use; D002540:Cerebral Cortex / Q000002:abnormalities; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D011379:Prognosis; D012008:Recurrence; D016896:Treatment Outcome
D000927:Anticonvulsants; D002220:Carbamazepine